Tag: NTLA-2002
The US FDA designates Intellia’s NTLA-2002, a regenerative medicine advanced therapy to treat hereditary angioedema.
The US Food and Drug Administration (FDA) has designated NTLA-2002 for the treatment of hereditary angioedema as a…
